{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:51:52Z","timestamp":1794329512041,"version":"4.9.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The prognostic heterogeneity of the World Health Organization category of \u201csystemic mastocytosis with associated clonal hematologic nonmast cell lineage disease\u201d (SM-AHNMD) has not been systematically validated by primary data. Among 138 consecutive cases with SM-AHNMD, 123 (89%) had associated myeloid neoplasm: 55 (45%) myeloproliferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndrome (SM-MDS), and 4 (3%) acute leukemia. Of the myeloid subgroups, SM-MPN displayed a 2- to 3-fold better life expectancy (P = .003), whereas leukemic transformation was more frequent in SM-MDS (29%; P = .02). The presence of eosinophilia, although prevalent (34%), was prognostically neutral, and the overall results were not affected by exclusion of FIP1L1-PDGFRA-positive cases. We conclude that it is clinically more useful to consider specific entities, such as SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytosis with-acute leukemia, rather than their broad reference as SM-AHNMD.<\/jats:p>","DOI":"10.1182\/blood-2009-05-220145","type":"journal-article","created":{"date-parts":[[2009,8,28]],"date-time":"2009-08-28T02:13:47Z","timestamp":1251425627000},"page":"3769-3772","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":161,"title":["Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies"],"prefix":"10.1182","volume":"114","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Hong","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"},{"name":"Division of Hematology-Oncology, Mackay Memorial Hospital, and Mackay Medicine, Nursing and Management College, Taipei, Taiwan, Republic of China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"McClure","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111722181643800_B1","first-page":"54","article-title":"Mastocytosis.","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Horny","year":"2008","edition":"4th ed."},{"issue":"5","key":"2019111722181643800_B2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders.","volume":"62","author":"Travis","year":"1988","journal-title":"Cancer"},{"issue":"6","key":"2019111722181643800_B3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.","volume":"57","author":"Horny","year":"2004","journal-title":"J Clin Pathol"},{"issue":"2","key":"2019111722181643800_B4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"issue":"7","key":"2019111722181643800_B5","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111722181643800_B6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111722181643800_B7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.leukres.2007.04.008","article-title":"Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.","volume":"31","author":"Kim","year":"2007","journal-title":"Leuk Res"},{"issue":"23","key":"2019111722181643800_B8","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111722181643800_B9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"2019111722181643800_B10","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/18\/3769\/1318833\/zh804409003769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/18\/3769\/1318833\/zh804409003769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T03:18:23Z","timestamp":1574047103000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/114\/18\/3769\/26573\/Prognostically-relevant-breakdown-of-123-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,29]]},"references-count":10,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2009,10,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-05-220145","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,29]]}}}